A practical reference on GHRH analogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-10 and is reviewed periodically as new material appears.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
To facilitate the work of the CDC, a Medical Laboratory Services Advisory Committee was appointed. Inhorn was the only State Laboratory Director to serve on the MLSAC Advisory Committee, perhaps because the WSLH had a strong history of proficiency testing in clinical laboratories in Wisconsin. Inhorn's assignment for CLIA-67 was to develop a protocol for PT programs to be used in the future. Many changes had been made to CLIA-67, but major weaknesses in the program still existed. It would take another two decades before new federal legislation, called CLIA-88, would address these shortcomings. Inhorn was appointed to the new CLIA-88 advisory board and served during the first two years of its existence. During the ensuing years, many more health laboratories opened in the U.S. and new technology introduced built-in controls, so that performance was validated without confirmation by laboratory workers.
Enzyme structures may also contain allosteric sites where the binding of a small molecule causes a conformational change that increases or decreases activity. A small number of RNA-based biological catalysts called ribozymes exist, which again can act alone or in complex with proteins. The most common of these is the ribosome which is a complex of protein and catalytic RNA components.
Radiation therapy has been used mostly for early-stage disease, but is unproven. Evidence to support its use as of 2017, however, was scarce—efforts to gather evidence are complicated due to a poor understanding of how the condition develops over time. It has been studied in early disease. The Royal College of Radiologists concluded that radiotherapy is effective in early stage disease which has progressed within the last 6 to 12 months.
== Function == The COL11A1 gene encodes one of the two alpha chains of type XI collagen, a minor fibrillar collagen. Type XI collagen is a heterotrimer but the third alpha chain is a post-translationally modified alpha 1 type II chain. Three transcript variants encoding different isoforms have been identified for this gene.
Sources: en.wikipedia.org
The part instead went to Martin Landau. Culp co-starred in The Greatest American Hero as tough veteran FBI Special Agent Bill Maxwell, who teams up with a high-school teacher who receives superpowers from extraterrestrials. He wrote and directed the second-season finale episode "Lilacs, Mr. Maxwell", with free rein to do the episode as he saw fit. The show lasted three years from 1981 to 1983. He reprised the role in the spin-off pilot The Greatest American Heroine. During that time, Culp was rumored to replace Larry Hagman as J. R. Ewing in Dallas. However, Culp firmly denied this, insisting he would never leave his role as Bill Maxwell. Culp reunited with Cosby on The Cosby Show in the episode "Bald and Beautiful" (1987), playing Dr. Cliff Huxtable's old friend Scott Kelly. The name was a combination of their I Spy characters' names. In I Spy Returns (1994), a nostalgic television movie, Culp and Cosby reprised their roles as Robinson and Scott for the first time since 1968. Culp and Cosby reunited one last time on the television show Cosby in an episode entitled "My Spy" (1999), in which Cosby's character, Hilton Lucas, dreams he is Alexander Scott on a mission with Kelly Robinson. Culp appeared on episodes of other television programs, including The Golden Girls where he played Simon, Blanche's beau, in the episode titled "Like the Beep Beep Beep of My Tom Tom" (1990), as well as Murder, She Wrote, Matlock, Who's the Boss?, Dr. Quinn, Medicine Woman, The Nanny, and Wings.
=== Legal status === Kostaive was approved for medical use in Japan in November 2023. In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kostaive, a vaccine intended for the prevention of COVID-19 in adults. The applicant for this medicinal product is Arcturus Therapeutics Europe B.V. Zapomeran was authorized for medical use in the European Union in February 2025, and in the UK in January 2026.
=== Relations with Tibet === In the fall of 1933, the 13th Dalai Lama sent an ultimatum to Liu Wenhui stating that Tibet would launch another attack if the 24th Army did not retreat further east. The ultimatum was not followed up because of the Lama's death on 17 December. In the wake of the ensuing political instability within the region, Liu cabled Nanjing for an expeditionary force to restore Chinese control over the entirety of Tibet. However, Dai Jitao and other close advisors to Chiang Kai-shek chose a more conciliatory policy and urged restraint on 23 December, which Liu Wenhui again ignored. Here, historian James Leibold speculates that Liu would probably have seized Lhasa had it not been for his untimely defeat at the hands of his nephew. In 1934, the new Tibetan government of Jamphel Yeshe Gyaltsen was ready to pursue peace with the central government, as the war with Liu had drained the monasteries' resources and driven up the price of Chinese tea. Chiang dispatched General Huang Musong on a diplomatic mission to Lhasa, with the aim of getting Tibet to accept Chinese sovereignty in exchange for broad autonomy. This mission, although accepted by the Kashag, was foiled when Liu Wenhui met with Huang in Chengdu and urged a hard line on the border issue. This was anathema to the Tibetans who wanted a demilitarized buffer zone in Xikang to protect from Liu Wenhui's army.
=== Laser research === Mester started his laser research in 1965. In 1974 he founded the Laser Research Center at Semmelweis, and continued working there for the remainder of his life. He is credited with the discovery of low level laser therapy. Mester's publications on the biostimulatory effects of the low intensity laser started in 1967. He performed early science experiments on the biological effects of laser irradiation. While applying lasers to the backs of shaven mice, Mester noticed that the shaved hair grew back more quickly on the treated group than the untreated group. Mester is believed to be only the fourth physician publishing in the area of laser medicine and surgery. In 1971, he began treating patients with non-healing skin ulcers, while using Low Intensity Laser Irradiation. Mester is the author of over 100 published articles in his areas of research. His two sons, Adam Mester, M.D. a radiologist, and Andrew Mester, M.D., an otolaryngologist, later assisted him in his work.
The set nature of species, and thus the absoluteness of creatures' places in the great chain, came into question during the 18th century. The dual nature of the chain, divided yet united, had always allowed for seeing creation as essentially one continuous whole, with the potential for overlap between the links. Radical thinkers like Jean-Baptiste Lamarck saw a progression of life forms from the simplest creatures striving towards complexity and perfection, a schema accepted by zoologists like Henri de Blainville. The very idea of an ordering of organisms, even if supposedly fixed, laid the basis for the idea of transmutation of species, whether progressive goal-directed orthogenesis or Charles Darwin's undirected theory of evolution. The chain of being continued to be part of metaphysics in 19th-century education, and the concept was well known. The geologist Charles Lyell used it as a metaphor in his 1851 Elements of Geology description of the geological column, where he used the term "missing links" about missing parts of the continuum. The term "missing link" later came to signify transitional fossils, particularly those bridging the gulf between man and beasts.
Sources: en.wikipedia.org
He signed the Epstein Files Transparency Act on November 19, and made a lengthy post on Truth Social which included the claim, "Do not forget — The Biden Administration did not turn over a SINGLE file or page related to Democrat Epstein, nor did they ever even speak about him.
== Description == The sucrose lysis test uses an isotonic sucrose solution to lower the ionic strength of serum, which triggers the activation of the classic complement pathway, leading to the lysis of cells that are sensitive to complement. In the sucrose lysis test, patient RBCs are washed and resuspended in a buffered sucrose solution. The solution is then incubated at a set temperature for a specified period, during which complement-mediated lysis occurs. After incubation, the solution is centrifuged, and the amount of hemoglobin released is measured spectrophotometrically. The degree of lysis is compared to that of control samples. Although more sensitive than the Ham test, it is not as specific since some RBCs hemolyze to a minor degree in autoimmune hemolytic anemias, leukemia, and aplastic anemia. Although affordable and straightforward to perform, the test is more labor-intensive because PNH RBCs have a short half-life in circulation.
Richardson and coworkers designed a 79-residue protein with no sequence homology to a known protein. In the 1990s, the advent of powerful computers, libraries of amino acid conformations, and force fields developed mainly for molecular dynamics simulations enabled the development of structure-based computational protein design tools. Following the development of these computational tools, great success has been achieved over the last 30 years in protein design. The first protein successfully designed completely de novo was done by Stephen Mayo and coworkers in 1997, and, shortly after, in 1999 Peter S. Kim and coworkers designed dimers, trimers, and tetramers of unnatural right-handed coiled coils. In 2003, David Baker's laboratory designed a full protein to a fold never seen before in nature. Later, in 2008, Baker's group computationally designed enzymes for two different reactions. In 2010, one of the most powerful broadly neutralizing antibodies was isolated from patient serum using a computationally designed protein probe. In 2024, Baker received one half of the Nobel Prize in Chemistry for his advancement of computational protein design, with the other half being shared by Demis Hassabis and John Jumper of Deepmind for protein structure prediction. Due to these and other successes (e.g., see examples below), protein design has become one of the most important tools available for protein engineering. There is great hope that the design of new proteins, small and large, will have uses in biomedicine and bioengineering.
== Side effects == Side effects of benzimidazole derived opioids are likely to be similar to those of fentanyl, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Isotonitazene has been detected in multiple fatalities in Europe since March 2019 and in the U.S. since August 2019, as reported by NPS Discovery, the Center for Forensic Science Research and Education, and NMS Labs.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.